Novo Nordisk Cuts Jobs: Ozempic's Reign in Question?
Update: 2025-09-10
Description
Ozempic maker Novo Nordisk slashes 9,000 jobs after profits plunge! Once Europe's most valuable company, the Danish giant is reeling from competition with Eli Lilly's Mounjaro and cheaper Ozempic alternatives. Shares plummeted, a CEO was ousted, and even Denmark's economy is feeling the pain. Can these drastic cuts save Novo Nordisk from a $70 billion market value wipeout?
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
